Indication

VIMPAT® (lacosamide) (C-V) is indicated in patients 17 years and older with partial-onset seizures as monotherapy or adjunctive therapy. VIMPAT (lacosamide) injection for intravenous use is an alternative when oral administration is temporarily not feasible.

Important Safety Information

Warnings and Precautions

  • Suicidal Behavior and Ideation:
    Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including VIMPAT, increase the risk of suicidal behavior and ideation. Patients taking VIMPAT should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Patients and caregivers should also be advised to be alert for these behavioral changes and to immediately report them to the healthcare provider.

Request Samples

You can request the 2-week sample kit either through your UCB sales representative or by calling UCBCares at 844-599-CARE (2273).

Patient Assistance

The UCB Patient Assistance Program helps eligible patients who cannot pay for their prescription epilepsy medications.

Get the Patient Application
Form Online


Visit the Patient Site

Contact Information
If you have any questions or want more information, please contact UCBCares at 844-599-CARE (2273) or ucbcares@ucb.com. We're here to help.

Important Safety Information (continued)

Warnings and Precautions

  • Dizziness and Ataxia: VIMPAT may cause dizziness and ataxia. Accordingly, patients should be advised not to drive a car or to operate other complex machinery until they are familiar with the effects of VIMPAT on their ability to perform such activities.

  • Cardiac Rhythm and Conduction Abnormalities:

    PR interval prolongation

    Dose-dependent prolongations in PR interval with VIMPAT have been observed in clinical studies in patients and in healthy volunteers. Second-degree and complete AV block have been reported in patients in pain studies and in patients with seizures. When VIMPAT is given with other drugs that prolong the PR interval, further PR prolongation is possible.

    VIMPAT should be used with caution in patients with known cardiac conduction problems (e.g., marked first-degree AV block, second-degree or higher AV block and sick sinus syndrome without pacemaker), sodium channelopathies (e.g., Brugada Syndrome), or with severe cardiac disease such as myocardial ischemia or heart failure, or structural heart disease. VIMPAT should be used with caution in patients on concomitant medications that prolong PR interval, because of a risk of AV block or bradycardia, e.g., beta-blockers and calcium channel blockers. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state, is recommended. In addition, these patients should be closely monitored if they are administered VIMPAT through the intravenous route.

    Atrial fibrillation and Atrial flutter

    VIMPAT administration may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy and/or cardiovascular disease.

  • Syncope: Patients should be advised that VIMPAT may cause syncope.

  • Withdrawal of Antiepileptic Drugs: VIMPAT should be gradually withdrawn (over a minimum of 1 week) to minimize the potential of increased seizure frequency.

  • Multiorgan Hypersensitivity Reactions: Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, or DRESS) have been reported with antiepileptic drugs. If this reaction is suspected, VIMPAT should be discontinued and alternative treatment started.

  • Phenylketonurics: VIMPAT oral solution contains aspartame, a source of phenylalanine. A 200 mg dose of VIMPAT oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Adverse Reactions

  • Adjunctive therapy: In the placebo-controlled clinical trials, the most frequently seen adverse reaction with VIMPAT was dizziness (31% vs 8% placebo). Other common adverse reactions occurring in ≥10 percent of VIMPAT-treated patients, and greater than placebo, were headache, nausea, and diplopia.

  • Monotherapy: In the clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%).

  • Injection: In adjunctive therapy clinical trials, adverse reactions with intravenous administration generally were similar to those observed with the oral formulation, although intravenous administration was associated with local adverse events such as injection site pain or discomfort (2.5%), irritation (1%), and erythema (0.5%). When administering a loading dose, the incidence of CNS adverse reactions, such as dizziness, somnolence, and paresthesia may be higher with 15-minute administration than over a 30- to 60-minute period.

Dosing Considerations

The loading dose should be administered with medical supervision considering the VIMPAT pharmacokinetics and increased incidence of CNS adverse reactions.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment. Use in patients with severe hepatic impairment is not recommended. Dose titration should be performed with caution in all patients with renal and/or hepatic impairment.

VIMPAT is a Schedule V controlled substance.

Please see VIMPAT Prescribing Information

VIMPAT is a registered trademark used under license from Harris FRC Corporation.
“UCB - Inspired by patients. Driven by science.” is a trademark of the UCB Group of companies.
©2014 UCB, Inc. Smyrna, GA 30080. All rights reserved.

LCM-PRM-033797-0814